Free Trial

Cartesian Therapeutics (RNAC) Financials

Cartesian Therapeutics logo
$10.00 +0.91 (+10.01%)
Closing price 04:00 PM Eastern
Extended Trading
$10.09 +0.09 (+0.89%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Cartesian Therapeutics

Annual Income Statements for Cartesian Therapeutics

This table shows Cartesian Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-77 -220 35
Consolidated Net Income / (Loss)
-77 -220 35
Net Income / (Loss) Continuing Operations
-77 -220 36
Total Pre-Tax Income
-77 -239 35
Total Operating Income
-44 -86 15
Total Gross Profit
39 26 111
Total Revenue
39 26 111
Operating Revenue
39 26 111
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
83 112 96
Selling, General & Admin Expense
30 40 24
Research & Development Expense
45 71 72
Impairment Charge
7.58 0.71 -
Total Other Income / (Expense), net
-33 -152 20
Interest Expense
0.00 2.83 3.03
Interest & Investment Income
7.39 4.96 2.07
Other Income / (Expense), net
-41 -154 21
Income Tax Expense
0.29 -19 -0.61
Basic Earnings per Share
($4.48) ($49.76) $0.24
Weighted Average Basic Shares Outstanding
17.28M 5.17M 144.76M
Diluted Earnings per Share
($4.49) ($49.76) $0.10
Weighted Average Diluted Shares Outstanding
17.36M 5.17M 145.87M
Weighted Average Basic & Diluted Shares Outstanding
25.91M 161.95M 153.32M

Quarterly Income Statements for Cartesian Therapeutics

This table shows Cartesian Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-6.05 -24 9.63 -57 -178 -9.00 -11 -22 5.89 -7.89
Consolidated Net Income / (Loss)
-10 -24 14 -57 -178 -9.00 -11 -22 5.89 -7.89
Net Income / (Loss) Continuing Operations
-12 -24 15 -57 -172 -13 -18 -18 1.58 -7.89
Total Pre-Tax Income
-10 -24 15 -57 -190 -13 -18 -18 1.11 -8.21
Total Operating Income
-27 -18 14 -13 -36 -13 -19 -18 -8.50 -1.60
Total Gross Profit
-0.76 0.39 33 5.84 8.27 6.55 5.25 5.94 17 21
Total Revenue
-0.76 0.39 33 5.84 8.27 6.55 5.25 5.94 17 21
Operating Revenue
-0.76 0.39 33 5.84 8.27 6.55 5.25 5.94 17 21
Total Operating Expenses
26 18 20 19 45 20 24 24 25 22
Selling, General & Admin Expense
7.09 6.56 7.03 9.45 22 6.61 6.11 5.70 6.32 5.77
Research & Development Expense
11 11 13 9.74 22 13 18 19 19 17
Total Other Income / (Expense), net
16 -6.86 1.20 -44 -154 0.02 0.67 0.54 9.28 -6.62
Interest & Investment Income
2.45 2.57 1.20 1.16 0.94 1.30 1.39 1.33 1.14 0.71
Basic Earnings per Share
($0.35) ($1.13) $0.58 ($10.50) ($34.36) ($1.74) ($2.23) ($4.24) $0.04 ($0.05)
Weighted Average Basic Shares Outstanding
17.28M 21.47M 16.72M 5.41M 5.17M 5.16M 5.11M 5.11M 144.76M 152.85M
Diluted Earnings per Share
($0.35) ($1.13) $0.54 ($10.50) ($34.36) ($1.74) ($2.23) ($4.24) $0.04 ($0.05)
Weighted Average Diluted Shares Outstanding
17.36M 21.47M 17.79M 5.41M 5.17M 5.16M 5.11M 5.11M 145.87M 152.85M
Basic & Diluted Earnings per Share
($0.35) - - - ($34.36) - - - $0.04 -
Weighted Average Basic & Diluted Shares Outstanding
25.91M 25.41M 21.38M 17.80M 161.95M 155.20M 153.43M 153.43M 153.32M 153.03M

Annual Cash Flow Statements for Cartesian Therapeutics

This table details how cash moves in and out of Cartesian Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
136 -30 -7.40
Net Cash From Operating Activities
-24 -51 -32
Net Cash From Continuing Operating Activities
-24 -51 -32
Net Income / (Loss) Continuing Operations
-77 -220 35
Consolidated Net Income / (Loss)
-77 -220 35
Depreciation Expense
1.15 0.84 1.29
Amortization Expense
0.00 -0.08 -0.38
Non-Cash Adjustments To Reconcile Net Income
61 182 -11
Changes in Operating Assets and Liabilities, net
-8.49 -14 -57
Net Cash From Investing Activities
-8.74 35 -15
Net Cash From Continuing Investing Activities
-8.74 35 -15
Purchase of Property, Plant & Equipment
-9.09 -0.21 -1.20
Acquisitions
0.00 6.56 0.00
Sale of Property, Plant & Equipment
0.35 0.00 -
Sale and/or Maturity of Investments
0.00 28 20
Net Cash From Financing Activities
168 -13 39
Net Cash From Continuing Financing Activities
168 -13 39
Repayment of Debt
0.00 -27 -0.11
Repurchase of Common Equity
-0.07 0.00 -
Issuance of Preferred Equity
40 20 0.00
Issuance of Common Equity
124 0.23 39
Other Financing Activities, net
4.06 -6.17 0.16
Effect of Exchange Rate Changes
-0.02 -0.05 0.02
Cash Interest Paid
0.00 1.85 2.25

Quarterly Cash Flow Statements for Cartesian Therapeutics

This table details how cash moves in and out of Cartesian Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-6.59 132 -16 27 -2.69 -34 -13 19 -6.41 -25
Net Cash From Operating Activities
-7.00 14 -14 -16 -23 -9.22 -9.90 -8.77 -12 4.35
Net Cash From Continuing Operating Activities
-7.00 14 -14 -16 -23 -9.22 -9.90 -8.77 -12 4.35
Net Income / (Loss) Continuing Operations
-10 -24 14 -57 -178 -9.00 -11 -22 5.89 -7.89
Consolidated Net Income / (Loss)
-10 -24 14 -57 -178 -9.00 -11 -22 5.89 -7.89
Depreciation Expense
0.49 0.29 0.20 0.18 0.27 0.19 0.18 0.21 0.24 0.35
Non-Cash Adjustments To Reconcile Net Income
-3.39 14 2.50 48 176 -1.19 -1.21 8.49 -13 9.34
Changes in Operating Assets and Liabilities, net
6.15 23 -31 -6.98 -22 0.79 2.53 4.28 -3.88 2.35
Net Cash From Investing Activities
-0.35 -6.20 -1.59 -0.60 6.50 - -0.01 28 5.49 -30
Net Cash From Continuing Investing Activities
-0.35 -6.20 -1.59 -0.60 6.50 - -0.01 28 5.63 -30
Purchase of Property, Plant & Equipment
-0.71 -6.20 -1.59 -0.60 -0.06 - -0.01 -0.13 -0.07 -0.58
Net Cash From Financing Activities
0.78 124 0.12 43 14 -25 -2.59 0.15 - 0.61
Net Cash From Continuing Financing Activities
0.78 124 0.12 43 14 -25 -2.59 0.15 - 0.61
Other Financing Activities, net
0.85 0.06 0.12 3.03 -6.17 - - 0.00 - 0.14
Effect of Exchange Rate Changes
-0.02 -0.02 0.01 -0.01 0.02 -0.02 -0.03 -0.02 - -

Annual Balance Sheets for Cartesian Therapeutics

This table presents Cartesian Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
435 305 166
Total Current Assets
217 91 148
Cash & Equivalents
213 77 106
Accounts Receivable
0.87 5.87 9.76
Prepaid Expenses
3.14 4.97 3.78
Other Current Assets
0.00 2.98 -
Plant, Property, & Equipment, net
9.91 2.11 2.79
Total Noncurrent Assets
208 212 15
Long-Term Investments
2.00 2.00 2.00
Goodwill
48 48 0.00
Intangible Assets
151 151 0.00
Other Noncurrent Operating Assets
6.05 10 12
Other Noncurrent Nonoperating Assets
1.67 1.38 1.31
Total Liabilities & Shareholders' Equity
435 305 166
Total Liabilities
442 445 72
Total Current Liabilities
23 68 25
Accounts Payable
0.29 3.15 0.32
Accrued Expenses
12 16 14
Current Deferred Revenue
0.00 2.31 0.59
Other Current Liabilities
11 47 1.61
Total Noncurrent Liabilities
419 380 47
Noncurrent Deferred Revenue
0.00 3.54 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
16 16 0.00
Other Noncurrent Operating Liabilities
403 361 29
Commitments & Contingencies
0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 297 0.00
Total Equity & Noncontrolling Interests
-6.80 -440 94
Total Preferred & Common Equity
-6.80 -440 94
Preferred Stock
0.00 0.00 0.00
Total Common Equity
-6.80 -440 94
Common Stock
690 179 493
Retained Earnings
-692 -615 -395
Accumulated Other Comprehensive Income / (Loss)
-4.62 -4.60 -4.56

Quarterly Balance Sheets for Cartesian Therapeutics

This table presents Cartesian Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
455 348 325 106 140 156 178
Total Current Assets
229 125 111 90 123 138 160
Cash & Equivalents
219 87 103 80 112 126 113
Accounts Receivable
4.83 32 2.01 4.90 5.39 6.84 6.93
Prepaid Expenses
4.13 2.04 3.32 3.49 4.26 3.79 6.31
Other Current Assets
0.98 3.47 2.37 1.88 1.06 1.84 -
Plant, Property, & Equipment, net
10 6.67 2.40 2.42 2.59 2.77 2.90
Total Noncurrent Assets
216 216 212 14 14 15 16
Long-Term Investments
2.00 2.00 2.00 2.00 2.00 2.00 2.00
Goodwill
48 48 48 - - - -
Intangible Assets
151 151 151 - - - -
Other Noncurrent Operating Assets
14 14 9.56 10 11 11 12
Other Noncurrent Nonoperating Assets
1.67 1.67 1.38 1.38 1.38 1.31 1.60
Total Liabilities & Shareholders' Equity
455 348 325 106 140 156 178
Total Liabilities
455 449 442 46 74 81 93
Total Current Liabilities
21 26 37 20 29 27 24
Accounts Payable
0.52 2.86 2.52 0.38 0.27 1.06 0.21
Accrued Expenses
9.45 11 9.52 14 13 9.35 12
Current Deferred Revenue
0.00 0.00 0.41 4.14 4.23 4.23 3.82
Other Current Liabilities
11 12 24 1.79 1.73 1.67 1.55
Total Noncurrent Liabilities
433 423 405 26 45 55 70
Noncurrent Deferred Revenue
0.00 0.00 0.00 3.98 4.86 5.52 5.44
Noncurrent Deferred & Payable Income Tax Liabilities
16 16 16 - - - -
Other Noncurrent Operating Liabilities
417 407 390 22 26 33 44
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 0.00 0.00 - - - -
Total Equity & Noncontrolling Interests
0.75 -101 -117 60 65 75 85
Total Preferred & Common Equity
0.75 -101 -117 60 65 75 85
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
0.75 -101 -117 60 65 75 85
Common Stock
687 561 559 502 498 496 490
Retained Earnings
-682 -658 -671 -437 -428 -417 -401
Accumulated Other Comprehensive Income / (Loss)
-4.61 -4.59 -4.61 -4.62 -4.60 -4.57 -4.53

Annual Metrics And Ratios for Cartesian Therapeutics

This table displays calculated financial ratios and metrics derived from Cartesian Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
49.64% -76.53% 30.21%
EBITDA Growth
65.27% -761.19% 905.46%
EBIT Growth
64.91% -780.38% 610.35%
NOPAT Growth
49.20% -508.93% 559.70%
Net Income Growth
64.76% -721.02% 237.73%
EPS Growth
90.98% -721.02% 145.45%
Operating Cash Flow Growth
53.73% -61.74% 47.62%
Free Cash Flow Firm Growth
-121.52% 386.81% 4.80%
Invested Capital Growth
0.24% -1,154.68% 78.60%
Revenue Q/Q Growth
-18.83% -24.70% -10.61%
EBITDA Q/Q Growth
-58.62% -379.77% -0.21%
EBIT Q/Q Growth
-57.99% -385.61% -1.92%
NOPAT Q/Q Growth
17.95% -47.52% -45.44%
Net Income Q/Q Growth
68.38% -507.62% -15.21%
EPS Q/Q Growth
61.29% -507.62% -62.96%
Operating Cash Flow Q/Q Growth
40.75% -28.79% 38.27%
Free Cash Flow Firm Q/Q Growth
-119.30% 353.17% 26.78%
Invested Capital Q/Q Growth
-0.43% -887.25% 54.35%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-214.25% -923.23% 32.78%
Operating Margin
-112.81% -332.32% 13.12%
EBIT Margin
-217.21% -926.17% 31.95%
Profit (Net Income) Margin
-198.97% -844.91% 31.94%
Tax Burden Percent
100.37% 92.04% 101.75%
Interest Burden Percent
91.26% 99.12% 98.23%
Effective Tax Rate
0.00% 0.00% -1.75%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
103.14% 887.63% 60.82%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-22.84% -102.28% 21.73%
Return on Assets (ROA)
-20.92% -93.31% 21.72%
Return on Common Equity (ROCE)
307.07% 6,210.18% 60.82%
Return on Equity Simple (ROE_SIMPLE)
1,138.25% 49.91% 37.71%
Net Operating Profit after Tax (NOPAT)
-31 -60 15
NOPAT Margin
-78.97% -232.62% 13.35%
Net Nonoperating Expense Percent (NNEP)
-31.49% -165.91% 18.93%
Return On Investment Capital (ROIC_SIMPLE)
451.75% 13.74% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
77.42% 155.55% 21.54%
R&D to Revenue
115.91% 274.03% 65.34%
Operating Expenses to Revenue
212.81% 432.32% 86.88%
Earnings before Interest and Taxes (EBIT)
-85 -241 35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-83 -240 36
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.00 0.00 1.84
Price to Tangible Book Value (P/TBV)
0.00 0.00 1.84
Price to Revenue (P/Rev)
11.70 4.11 1.56
Price to Earnings (P/E)
0.00 0.00 4.89
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 20.46%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
6.18 12.50 0.57
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 1.72
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 1.77
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 4.23
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 2.24 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.28
Long-Term Debt to Equity
0.00 0.00 0.19
Financial Leverage
1.98 3.88 -1.87
Leverage Ratio
-4.93 -9.51 2.80
Compound Leverage Factor
-4.50 -9.43 2.75
Debt to Total Capital
0.00% 0.00% 21.87%
Short-Term Debt to Total Capital
0.00% 0.00% 7.06%
Long-Term Debt to Total Capital
0.00% 0.00% 14.81%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% -207.11% 0.00%
Common Equity to Total Capital
100.00% 307.11% 78.13%
Debt to EBITDA
0.00 0.00 0.72
Net Debt to EBITDA
0.00 0.00 -3.04
Long-Term Debt to EBITDA
0.00 0.00 0.49
Debt to NOPAT
0.00 0.00 1.78
Net Debt to NOPAT
0.00 0.00 -7.46
Long-Term Debt to NOPAT
0.00 0.00 1.20
Altman Z-Score
-1.63 -5.11 0.37
Noncontrolling Interest Sharing Ratio
-197.72% -599.64% 0.00%
Liquidity Ratios
- - -
Current Ratio
9.43 1.33 5.91
Quick Ratio
9.29 1.21 5.76
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-31 145 -51
Operating Cash Flow to CapEx
-270.81% -24,835.44% -2,633.72%
Free Cash Flow to Firm to Interest Expense
0.00 51.29 -16.72
Operating Cash Flow to Interest Expense
0.00 -18.06 -10.44
Operating Cash Flow Less CapEx to Interest Expense
0.00 -18.13 -10.83
Efficiency Ratios
- - -
Asset Turnover
0.11 0.11 0.68
Accounts Receivable Turnover
11.54 3.33 11.26
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
6.47 10.60 44.89
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
31.62 109.68 32.41
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
31.62 109.68 32.41
Capital & Investment Metrics
- - -
Invested Capital
-223 -224 -18
Invested Capital Turnover
-0.17 -0.22 -2.19
Increase / (Decrease) in Invested Capital
0.54 -206 65
Enterprise Value (EV)
241 325 63
Market Capitalization
455 107 173
Book Value per Share
($0.27) ($2.84) $0.61
Tangible Book Value per Share
($8.09) ($4.12) $0.61
Total Capital
-6.80 -143 120
Total Debt
0.00 0.00 26
Total Long-Term Debt
0.00 0.00 18
Net Debt
-215 -79 -110
Capital Expenditures (CapEx)
8.74 0.21 1.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-19 -54 -3.07
Debt-free Net Working Capital (DFNWC)
194 23 132
Net Working Capital (NWC)
194 23 123
Net Nonoperating Expense (NNE)
47 159 -21
Net Nonoperating Obligations (NNO)
-216 -80 -112
Total Depreciation and Amortization (D&A)
1.15 0.76 0.91
Debt-free, Cash-free Net Working Capital to Revenue
-48.72% -209.16% -2.77%
Debt-free Net Working Capital to Revenue
497.65% 86.60% 118.74%
Net Working Capital to Revenue
497.65% 86.60% 111.09%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($4.48) ($49.80) $7.20
Adjusted Weighted Average Basic Shares Outstanding
17.28M 5.17M 4.83M
Adjusted Diluted Earnings per Share
($4.49) ($49.80) $3.00
Adjusted Weighted Average Diluted Shares Outstanding
17.36M 5.17M 4.86M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.91M 5.40M 5.11M
Normalized Net Operating Profit after Tax (NOPAT)
-25 -60 10
Normalized NOPAT Margin
-65.33% -230.71% 9.19%
Pre Tax Income Margin
-198.23% -917.97% 31.39%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 -85.01 11.68
NOPAT to Interest Expense
0.00 -21.35 4.88
EBIT Less CapEx to Interest Expense
0.00 -85.09 11.28
NOPAT Less CapEx to Interest Expense
0.00 -21.43 4.48
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.09% 0.00% 0.00%

Quarterly Metrics And Ratios for Cartesian Therapeutics

This table displays calculated financial ratios and metrics derived from Cartesian Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
-109.18% -94.09% 537.17% -1.65% -50.78% -68.37% -86.63% -82.53% -43.90% -15.22%
EBITDA Growth
86.22% -107.47% 175.67% -219.79% -39,021.97% -70.31% -228.07% -160.86% -176.57% -2,716.61%
EBIT Growth
85.99% -106.66% 173.90% -218.57% -42,593.54% -60.88% -235.32% -162.63% -60.72% -494.66%
NOPAT Growth
26.43% -34.52% 205.45% 27.38% -199.35% -717.07% -194.13% -219.43% -308.34% 18.79%
Net Income Growth
94.23% -168.64% 221.51% -162.31% -3,114.73% -14.05% -232.39% -175.28% -51.85% 55.89%
EPS Growth
98.98% 35.06% 124.22% -162.31% -3,114.73% -14.05% -232.39% -175.28% -63.64% 68.75%
Operating Cash Flow Growth
69.93% 248.57% -45.99% -81.60% -96.52% -311.69% 19.36% 26.12% 62.34% 140.51%
Free Cash Flow Firm Growth
-110.67% 832.95% 1,158.46% 876.25% 343.90% 73.79% 80.38% 74.41% -61.05% -2,857.73%
Invested Capital Growth
0.24% -880.60% -641.71% -692.58% -1,154.68% 41.98% 13.29% 28.24% 78.60% 71.15%
Revenue Q/Q Growth
-296.12% -98.84% 472.69% -29.35% 26.18% 24.80% -11.60% -64.64% -18.90% -47.27%
EBITDA Q/Q Growth
1.78% -291.50% 123.93% 70.03% -1,379.34% 30.15% -1.12% -3,644.35% 93.56% -152.52%
EBIT Q/Q Growth
1.02% -296.31% 123.52% 69.98% -1,360.02% 29.80% -1.38% -4,189.53% 105.53% -159.05%
NOPAT Q/Q Growth
-52.10% -189.43% 247.23% 63.26% -178.09% 29.90% -1.40% -51.44% -659.05% -108.08%
Net Income Q/Q Growth
57.60% -274.78% 124.35% 68.02% -1,873.54% 20.94% 47.44% -467.61% 174.66% -191.77%
EPS Q/Q Growth
69.03% -309.26% 105.14% 68.02% -1,873.54% 20.94% 47.44% -467.61% 180.00% -183.33%
Operating Cash Flow Q/Q Growth
-151.14% 194.77% 9.24% 31.65% -152.70% 6.87% -12.89% 26.03% -372.20% 135.47%
Free Cash Flow Firm Q/Q Growth
-110.29% 3.88% -3.15% 3.15% 806.33% -50.01% 28.97% 67.59% 24.09% -12.31%
Invested Capital Q/Q Growth
-0.43% -15.47% 13.97% 0.01% -887.25% 12.66% 8.07% -58.28% 54.35% -30.53%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% -6,904.39% 41.72% -998.51% -2,304.91% -196.60% -351.29% -307.09% -2.90% -36.51%
Operating Margin
0.00% -4,541.34% 41.13% -228.56% -439.54% -199.44% -355.08% -309.55% -50.59% -7.72%
EBIT Margin
0.00% -6,978.29% 41.13% -1,001.64% -2,308.20% -199.48% -354.64% -309.23% 2.67% -39.22%
Profit (Net Income) Margin
0.00% -6,248.84% 41.37% -973.01% -2,149.26% -137.41% -216.94% -364.82% 35.09% -38.11%
Tax Burden Percent
99.31% 98.98% 92.54% 99.11% 93.58% 69.02% 63.36% 121.44% 529.95% 96.09%
Interest Burden Percent
38.62% 90.47% 108.69% 98.01% 99.51% 99.80% 96.55% 97.15% 247.66% 101.12%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
103.14% -801.65% 1,275.47% 1,207.32% 887.63% -49.79% -45.21% -23.11% 60.82% 126.10%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -1,191.86% 9.13% -107.92% -254.91% -48.46% -105.43% -169.74% 1.82% -28.14%
Return on Assets (ROA)
0.00% -1,067.27% 9.19% -104.83% -237.35% -33.38% -64.49% -200.25% 23.86% -27.34%
Return on Common Equity (ROCE)
307.07% -801.65% 1,275.47% 1,207.32% 6,210.18% -49.79% -45.21% -23.11% 60.82% 126.10%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 226.35% 218.21% 0.00% -59.94% -53.55% -20.20% 0.00% 49.14%
Net Operating Profit after Tax (NOPAT)
-19 -12 14 -9.34 -25 -9.15 -13 -13 -8.50 -1.12
NOPAT Margin
0.00% -3,178.94% 41.13% -159.99% -307.67% -139.60% -248.55% -216.68% -50.59% -5.40%
Net Nonoperating Expense Percent (NNEP)
5.70% -7.77% 0.09% -45.31% -158.62% 0.14% 1.57% -8.89% 13.23% -5.63%
Return On Investment Capital (ROIC_SIMPLE)
275.09% - - - 5.78% - - - - -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 1,695.61% 21.01% 161.82% 266.59% 100.96% 116.31% 95.91% 37.65% 27.86%
R&D to Revenue
0.00% 2,945.74% 37.86% 166.75% 264.36% 198.47% 338.77% 313.64% 112.93% 79.86%
Operating Expenses to Revenue
0.00% 4,641.34% 58.87% 328.56% 539.54% 299.44% 455.08% 409.55% 150.59% 107.72%
Earnings before Interest and Taxes (EBIT)
-27 -27 14 -58 -191 -13 -19 -18 0.45 -8.12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-26 -27 14 -58 -191 -13 -18 -18 -0.49 -7.56
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 458.36 0.00 0.00 0.00 2.70 2.63 2.86 1.84 2.95
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 2.70 2.63 2.86 1.84 2.95
Price to Revenue (P/Rev)
11.70 7.19 8.88 4.06 4.11 4.71 3.53 2.58 1.56 2.02
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.89 6.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.46% 16.66%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
6.18 2.58 7.24 0.00 12.50 2.35 1.68 1.35 0.57 1.03
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.72 3.52
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.77 3.55
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.23 4.72
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.76 2.96 0.00 2.24 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.37 0.35 0.28 0.31
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.22 0.19 0.24
Financial Leverage
1.98 -5.01 5.06 4.96 3.88 -1.42 -1.36 -1.52 -1.87 -3.64
Leverage Ratio
-4.93 9.19 -13.53 -11.39 -9.51 1.96 2.11 2.31 2.80 5.22
Compound Leverage Factor
-1.90 8.31 -14.71 -11.16 -9.47 1.95 2.04 2.25 6.93 5.28
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.85% 26.18% 21.87% 23.51%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11.44% 10.11% 7.06% 5.30%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.41% 16.06% 14.81% 18.21%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% -207.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 307.11% 100.00% 73.15% 73.82% 78.13% 76.49%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 -0.54 -2.23 0.72 0.72
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 2.01 8.54 -3.04 -3.36
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 -0.31 -1.37 0.49 0.56
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 -0.73 -2.58 1.78 0.96
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 2.73 9.92 -7.46 -4.51
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 -0.42 -1.59 1.20 0.75
Altman Z-Score
-1.19 -1.18 -1.38 -2.99 -4.57 -2.92 -2.19 -1.17 -0.33 -0.08
Noncontrolling Interest Sharing Ratio
-197.72% 0.00% 0.00% 0.00% -599.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
9.43 10.70 4.78 3.03 1.33 4.51 4.18 5.22 5.91 6.73
Quick Ratio
9.29 10.47 4.57 2.88 1.21 4.24 4.00 5.00 5.76 6.46
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-19 187 180 186 180 -26 -17 -24 -74 -97
Operating Cash Flow to CapEx
-993.19% 220.86% -910.27% -2,644.02% -36,384.38% 0.00% -82,458.33% -6,742.31% -17,953.03% 749.23%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 -20.06 -22.64 -29.66 -91.64 -121.47
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 -7.24 -13.16 -10.85 -14.68 5.43
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -7.24 -13.17 -11.01 -14.76 4.70
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.11 0.17 0.22 0.11 0.11 0.24 0.30 0.55 0.68 0.72
Accounts Receivable Turnover
11.54 9.86 2.89 5.86 3.33 5.84 3.31 11.82 11.26 17.39
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
6.47 7.58 11.68 10.03 10.60 12.97 17.95 30.33 44.89 52.61
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
31.62 37.03 126.24 62.31 109.68 62.48 110.11 30.87 32.41 20.99
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
31.62 37.03 126.24 62.31 109.68 62.48 110.11 30.87 32.41 20.99
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-223 -222 -192 -224 -224 -23 -26 -28 -18 -39
Invested Capital Turnover
-0.17 -0.39 -0.50 -0.21 -0.22 -1.12 -1.74 -2.45 -2.19 -1.42
Increase / (Decrease) in Invested Capital
0.54 -199 -166 -195 -206 16 3.98 11 65 96
Enterprise Value (EV)
241 123 391 -0.15 325 81 82 112 63 128
Market Capitalization
455 345 481 105 107 163 172 213 173 250
Book Value per Share
($0.27) $0.04 ($5.70) ($0.72) ($2.84) $0.39 $0.43 $0.49 $0.61 $0.56
Tangible Book Value per Share
($8.09) ($9.26) ($16.87) ($1.95) ($4.12) $0.39 $0.43 $0.49 $0.61 $0.56
Total Capital
-6.80 0.75 -101 -117 -143 60 89 101 120 111
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 24 26 26 26
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 14 16 18 20
Net Debt
-215 -221 -89 -105 -79 -82 -90 -101 -110 -122
Capital Expenditures (CapEx)
0.71 6.20 1.59 0.60 0.06 0.00 0.01 0.13 0.07 0.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-19 -11 11 -29 -54 -9.67 -8.43 -3.85 -3.07 -4.61
Debt-free Net Working Capital (DFNWC)
194 208 99 74 23 70 104 122 132 142
Net Working Capital (NWC)
194 208 99 74 23 70 93 112 123 136
Net Nonoperating Expense (NNE)
-8.46 12 -0.08 47 152 -0.14 -1.66 8.80 -14 6.77
Net Nonoperating Obligations (NNO)
-216 -223 -91 -107 -80 -83 -91 -103 -112 -124
Total Depreciation and Amortization (D&A)
0.49 0.29 0.20 0.18 0.27 0.19 0.18 0.13 -0.94 0.56
Debt-free, Cash-free Net Working Capital to Revenue
-48.72% -23.92% 21.15% -111.80% -209.16% -28.01% -17.32% -4.65% -2.77% -3.72%
Debt-free Net Working Capital to Revenue
497.65% 433.33% 182.37% 287.40% 86.60% 202.50% 212.75% 147.59% 118.74% 114.45%
Net Working Capital to Revenue
497.65% 433.33% 182.37% 287.40% 86.60% 202.50% 191.73% 135.24% 111.09% 109.71%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.35) ($1.13) $0.58 ($10.50) ($1,030.80) ($1.80) ($2.10) ($4.20) $1.20 ($1.50)
Adjusted Weighted Average Basic Shares Outstanding
17.28M 21.47M 16.72M 5.41M 172.34K 5.16M 5.11M 5.11M 4.83M 5.10M
Adjusted Diluted Earnings per Share
($0.35) ($1.13) $0.54 ($10.50) ($1,030.80) ($1.80) ($2.10) ($4.20) $1.20 ($1.50)
Adjusted Weighted Average Diluted Shares Outstanding
17.36M 21.47M 17.79M 5.41M 172.34K 5.16M 5.11M 5.11M 4.86M 5.10M
Adjusted Basic & Diluted Earnings per Share
($0.35) $0.00 $0.00 $0.00 ($1,030.80) $0.00 $0.00 $0.00 $1.20 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.91M 25.41M 21.38M 17.80M 5.40M 5.17M 5.11M 5.11M 5.11M 5.10M
Normalized Net Operating Profit after Tax (NOPAT)
-19 -12 9.63 -9.34 -25 -9.15 -13 -13 -5.95 -1.12
Normalized NOPAT Margin
0.00% -3,178.94% 28.79% -159.99% -307.67% -139.60% -248.55% -216.68% -35.41% -5.40%
Pre Tax Income Margin
0.00% -6,313.44% 44.71% -981.71% -2,296.83% -199.08% -342.41% -300.42% 6.62% -39.66%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -10.27 -24.75 -22.73 0.56 -10.13
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -7.18 -17.35 -15.92 -10.53 -1.40
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -10.27 -24.77 -22.89 0.47 -10.85
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -7.18 -17.37 -16.09 -10.61 -2.12
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Cartesian Therapeutics' Financials

When does Cartesian Therapeutics's financial year end?

According to the most recent income statement we have on file, Cartesian Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Cartesian Therapeutics' net income changed over the last 2 years?

Cartesian Therapeutics' net income appears to be on an upward trend, with a most recent value of -$77.42 million in 2024, falling from $35.38 million in 2022. The previous period was -$219.71 million in 2023. Check out Cartesian Therapeutics' forecast to explore projected trends and price targets.

What is Cartesian Therapeutics's operating income?
Cartesian Therapeutics's total operating income in 2024 was -$43.90 million, based on the following breakdown:
  • Total Gross Profit: $38.91 million
  • Total Operating Expenses: $82.81 million
How has Cartesian Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Cartesian Therapeutics' total revenue changed from $110.78 million in 2022 to $38.91 million in 2024, a change of -64.9%.

How much debt does Cartesian Therapeutics have?

Cartesian Therapeutics' total liabilities were at $441.83 million at the end of 2024, a 0.6% decrease from 2023, and a 513.2% increase since 2022.

How much cash does Cartesian Therapeutics have?

In the past 2 years, Cartesian Therapeutics' cash and equivalents has ranged from $76.91 million in 2023 to $212.61 million in 2024, and is currently $212.61 million as of their latest financial filing in 2024.

How has Cartesian Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Cartesian Therapeutics' book value per share changed from 0.61 in 2022 to -0.27 in 2024, a change of -143.6%.



This page (NASDAQ:RNAC) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners